Of the remaining six EGFR-mutant NSCLC patients, one patient was treated on a clinical trial that did not include an EGFR inhibitor, one patient was referred to hospice, one patient died soon after being seen, and three patients were treated with single-agent erlotinib by their primary oncologist or on study. Here, EGFR is linked to non-small cell lung carcinoma.